This is a randomized, double-blind, placebo-controlled parallel group outpatient 42-day
treatment study that will utilize standard stroke rehabilitation outcome measures to evaluate
the effect of DNS-3379 on upper extremity motor recovery in subjects following ischemic
stroke.